AI‐Driven Synthesis in Medicinal Chemistry: Integrating Large Language Models, Robotic Automation, and Sustainability Metrics to Accelerate Drug Discovery
Medicinal Research Reviews · 2026-11 · 46 (6) · 1798-1823
DOI: 10.1002/med.70074 ↗Abstract
ABSTRACT Artificial intelligence (AI) is transforming synthetic chemistry from task‐specific predictors into integrated platforms that unify retrosynthesis, reaction optimization, and closed‐loop robotic automation. This review highlights how AI‐assisted planning and robotic execution shorten cycle times, reduce step counts, and improve route sustainability in medicinal chemistry. Recent advances, including large language models (LLMs), template‐free retrosynthesis, and Bayesian optimization, are evaluated alongside key limitations in dataset quality, reproducibility, and deployment costs. To ensure translational relevance, reproducible benchmarks such as step count, time‐to‐in vitro, and green metrics (E‐factor, process mass intensity) are emphasized. This review proposes a hierarchical framework structured across three interconnected levels: cognitive planning, physical execution, and translational evaluation. Within this structure, key elements include LLM‐based synthesis planning, robotic and closed‐loop execution, interpretable decision‐making, sustainability‐by‐design, advanced reaction optimization, and multi‐objective retrosynthesis. Together, these components provide a conceptual basis for integrating digital intelligence with physical experimentation. By embedding green chemistry principles and regulatory awareness, AI is increasingly positioned not only as a predictive tool but also as an assistive collaborator supporting decision‐making in medicinal chemistry workflows. The convergence of AI, robotics, and sustainability metrics highlights an emerging transition; however, realizing a future where every experiment reliably feeds back into autonomous learning loops requires overcoming significant current barriers in data standardization and hardware interoperability.
EUVIMED